产品
编 号：F515362
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 909395-70-6
产品详情
生物活性：
Romosozumab is a humanized monoclonal anti-sclerostin antibody, it promotes bone formation and inhibits bone resorption by inhibiting sclerostin. Romosozumab can be used for the research of osteoporosis.
体内研究：
Romosozumab (30 mg/kg; s.c. twice a week for 10 weeks) converts trabecular rods into trabecular plates in cynomolgus monkeys.Romosozumab (3 and 30 mg/kg; s.c. once a week for 6 or 12 months) improves bone mass,architecture, and bone strength, and maintains bone quality at the same time in mature cynomolgus monkeys with 4 months post-ovariectomy.Animal Model:Male cynomolgus monkeys
Dosage:30 mg/kg
Administration:Subcutaneous injection; 30 mg/kg twice a week for 10 weeks
Result:Increased bone formation and plate-like trabecular morphology, and improved mechanical performance.
Romosozumab is a humanized monoclonal anti-sclerostin antibody, it promotes bone formation and inhibits bone resorption by inhibiting sclerostin. Romosozumab can be used for the research of osteoporosis.
体内研究：
Romosozumab (30 mg/kg; s.c. twice a week for 10 weeks) converts trabecular rods into trabecular plates in cynomolgus monkeys.Romosozumab (3 and 30 mg/kg; s.c. once a week for 6 or 12 months) improves bone mass,architecture, and bone strength, and maintains bone quality at the same time in mature cynomolgus monkeys with 4 months post-ovariectomy.Animal Model:Male cynomolgus monkeys
Dosage:30 mg/kg
Administration:Subcutaneous injection; 30 mg/kg twice a week for 10 weeks
Result:Increased bone formation and plate-like trabecular morphology, and improved mechanical performance.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备